Please assess the completion status of the following clinical trial:

Trial Title: CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of advanced non small cell lung cancer, not amenable to surgical or curative radiation therapy (stage IIIB or IV);~* No prior or concomitant chemotherapy (adjuvant/neoadjuvant chemotherapy permitted if concluded at least one year prior to enrollment);~* ECOG performance status 2;~* Age: \> or = 18 and \< 70 years;~* Life expectancy at least 4 weeks;~* Normal bone marrow, hepatic and renal function defined as: neutrophils \> or = 2000/mm3, PLT \> or = 100,000/mm3, Hb \> or = 10.0 g/dl, Bilirubin \> or = 1.5 times the upper normal limit (UNL), AST and ALT \< or = 3 times the UNL (5 times in the presence of liver metastases), creatinine within normal limits;~* Signed informed consent.~Exclusion Criteria:~* Active systemic infections;~* Severe concomitant illness (congestive heart failure, angina pectoris, myocardial infarction within previous 6 months, cardiac arrhythmias under treatment, severe arterial hypertension, severe or uncontrolled diabetes mellitus);~* Inadequate hepatic or renal function;~* Radiation therapy ongoing or concluded within two weeks prior to enrollment;~* Symptomatic cerebral metastases;~* Previous chemotherapy for advanced disease;~* Any condition that would, in the investigator's opinion, limit the patients ability to provide informed consent or to comply with study procedures;~* Pregnant or nursing females;~* Any malignancy within the past 5 years (except for adequately treated carcinoma in situ of the cervix or non melanoma skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm B (Type: EXPERIMENTAL): combination chemotherapy
- Arm A (Type: ACTIVE_COMPARATOR): monochemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).